title: A phase II trial of intermittent leukocyte interferon and high dose chlorambucil in the treatment of non-Hodgkin's lymphoma resistant to conventional therapy.
abstract: Thirteen patients with advanced non-Hodgkin's lymphoma who previously failed conventional chemotherapy protocols were treated with a combination of alpha-interferon (IFN) 6,000,000 units i.m. days 1-5 and 8, plus chlorambucil (CLB) 16 mg/m2 days 5-9 repeated every 4 weeks. There were five complete responses (CRs) and one partial response (PR) (46% total responses) with mean duration of remission of 456+ days. Responses were obtained in low and intermediate grade lymphomas. Toxicity was acceptable and easily managed. It is unlikely that IFN alone using this low dose intermittent schedule is responsible for the remissions. The combination of the two agents appears to be an effective treatment modality. IFN may be functioning as a biological response modifier when used in combination with a cytotoxic agent.
authors.affiliation: Michigan State University Cancer Treatment Consortium, East Lansing.
authors.forename: R H
authors.initials: RH
authors.lastname: Clark
authors.forename: N V
authors.initials: NV
authors.lastname: Dimitrov
authors.forename: J A
authors.initials: JA
authors.lastname: Axelson
authors.forename: L J
authors.initials: LJ
authors.lastname: Charamella
authors.forename: P B
authors.initials: PB
authors.lastname: Stott
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002699:Chlorambucil / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004347:Drug Interactions; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage* / Q000009:adverse effects; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008875:Middle Aged; D012074:Remission Induction; D013997:Time Factors
chemical_list: D007370:Interferon Type I; D002699:Chlorambucil